Astrazeneca Plc $AZN Stock Holdings Lessened by Private Advisor Group LLC

Private Advisor Group LLC cut its holdings in Astrazeneca Plc (NYSE:AZN) by 49.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 52,611 shares of the company’s stock after selling 51,082 shares during the period. Private Advisor Group LLC’s holdings in Astrazeneca were worth $10,376,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Triumph Capital Management bought a new position in Astrazeneca in the third quarter worth about $25,000. MV Capital Management Inc. acquired a new position in Astrazeneca in the fourth quarter valued at approximately $26,000. Bangor Savings Bank grew its holdings in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca during the 4th quarter worth approximately $30,000. Finally, YANKCOM Partnership bought a new stake in shares of Astrazeneca in the 4th quarter worth approximately $31,000. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on AZN shares. Bank of America restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. UBS Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Finally, TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Astrazeneca presently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Down 0.1%

AZN opened at $194.96 on Monday. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The stock has a market cap of $302.36 billion, a P/E ratio of 29.27, a P/E/G ratio of 1.58 and a beta of 0.24. The stock’s 50 day moving average price is $183.96 and its 200 day moving average price is $188.25.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. As a group, research analysts predict that Astrazeneca Plc will post 10.28 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.